Mirati Therapeutics reported $1.13B in Equity Capital and Reserves for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Agios Pharmaceuticals AGIO:US USD 1.05B 73.9M
Alnylam Pharmaceuticals ALNY:US USD -67638000 243.68M
Amgen AMGN:US USD 3.66B 8M
AstraZeneca AZN:LN USD 35.13B 798M
Bayer BAYN:GR EUR 41.27B 3.25B
Biocryst Pharmaceuticals BCRX:US USD -242659000 29.43M
Bluebird Bio BLUE:US USD 158.86M 21.26M
Exelixis EXEL:US USD 2.49B 100.14M
Gilead Sciences GILD:US USD 21.21B 128M
GlaxoSmithKline GSK:LN GBP 10.6B 1.45B
Moderna Inc MRNA:US USD 17.99B 7M
Nektar Therapeutics NKTR:US USD 412.22M 46.51M
Novartis NOVN:VX USD 60.82B 2.1B
Puma Biotechnology PBYI:US USD 22.15M 2.42M
Roche Holding ROG:VX 25.19B 700M
Sarepta Therapeutics SRPT:US USD 430.84M 295.62M
Seattle Genetics SGEN:US USD 2.82B 111M
Spectrum Pharmaceuticals SPPI:US USD 35.85M 2.41M
Takeda 4502:JP JPY 6.18T 536.95B
Ultragenyx Pharmaceutical RARE:US USD 468.83M 209.24M
YTE INCY:US USD 4.23B 141.59M